The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care

[1] James SL(2018)Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet 392 1789-1858

[2] Abate D(2013)Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010 PLoS Med 10 997-1008

[3] Abate KH(2000)Who uses mental health services in Australia? An analysis of data from the National Survey of Mental Health and Wellbeing Aust N Z J Psychiatry 34 1905-1917

[4] Ferrari AJ(2015)Antidepressant efficacy and side-effect burden: a quick guide for clinicians Drugs Context 4 189-198

[5] Charlson FJ(2006)Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report Am J Psychiatry 163 977-987

[6] Norman RE(2010)Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression Int Clin Psychopharmacol 25 679-682

[7] Parslow RA(2014)A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013 Psychiatr Serv 65 662-673

[8] Jorm AF(2013)Contribution of common genetic variants to antidepressant response Biol Psychiatry 73 37-44

[9] Santarsieri D(2011)Pharmacogenetics: from bench to byte—an update of guidelines Clin Pharmacol Ther 89 100-105

[10] Schwartz TL(2017)Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update Clin Pharmacol Ther 102 1303-1317

[1] James SL(2018)Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet 392 1789-1858

[2] Abate D(2013)Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010 PLoS Med 10 997-1008

[3] Abate KH(2000)Who uses mental health services in Australia? An analysis of data from the National Survey of Mental Health and Wellbeing Aust N Z J Psychiatry 34 1905-1917

[4] Ferrari AJ(2015)Antidepressant efficacy and side-effect burden: a quick guide for clinicians Drugs Context 4 189-198

[5] Charlson FJ(2006)Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report Am J Psychiatry 163 977-987

[6] Norman RE(2010)Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression Int Clin Psychopharmacol 25 679-682

[7] Parslow RA(2014)A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013 Psychiatr Serv 65 662-673

[8] Jorm AF(2013)Contribution of common genetic variants to antidepressant response Biol Psychiatry 73 37-44

[9] Santarsieri D(2011)Pharmacogenetics: from bench to byte—an update of guidelines Clin Pharmacol Ther 89 100-105

[10] Schwartz TL(2017)Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update Clin Pharmacol Ther 102 1303-1317